---
layout: default
---
<link rel="stylesheet" type="text/css" href="../css/main.css" />
<style>
.collapsible {
  background-color: #777;
  color: white;
  cursor: pointer;
  padding: 18px;
  width: 100%;
  border: none;
  text-align: left;
  outline: none;
  font-size: 15px;
}

.active, .collapsible:hover {
  background-color: #555;
}

.collapsible:after {
  content: '\002B';
  color: white;
  font-weight: bold;
  float: right;
  margin-left: 5px;
  font-family: Arial, sans-serif;
}

.active:after {
  content: "\2212";
}

.content {
  padding: 0px 10px;
  max-height: 0;
  overflow: hidden;
  transition: max-height 0.3s ease-out;
  background-color: #f1f1f1;
  font-family: Arial, sans-serif;
      list-style-type: disc;
    list-style-position: inside;
}
ul li { padding: 5px 15px;
        font-family: Arial, sans-serif;
          font-size: 13.5px;
}

</style>
</head>
<body>

<h2>Employment</h2>
 
<button class="collapsible">Technical Lead, SARS-CoV-2 Serology – PHE Porton</button>
<div class="content">
<b><p align="justify">September 2020 - Present<br></b></br>
  Responsible for overseeing high-throughput serology testing for population-wide sero-surveillance studies, research projects, convalescent screening and vaccine evaluations within PHE Porton. 
Involved in implementation and evaluation of new testing platforms and assays (Roche, Siemens, Euroimmun, Beckman, DiaSorin).

Supervision of a team of 8 scientists focussed on multi-platform testing and reporting.
<ul>
</div>
<button class="collapsible">Research Scientist – Diagnostic Support, PHE Porton</button>
<div class="content">
<b><p align="justify">March 2019 - Present<br></b></br>
  Research scientist within the Diagnostics and Genomics/Diagnostic Support (DSP) team for the Rare and Imported Pathogens Laboratory (RIPL). Duties and responsibilities include:
<ul>
<li>Involved in research, evaluation and validation of new molecular diagnostics for a wide range of ACDP 2, 3 and 4 pathogens including but not limited to: haemorrhagic fevers (Pan-filovirus, CCHF, Lassa), arboviruses (Zika, Rift Valley Fever, WNV) and high pathogenicity bacteria/viruses (B. anthracis, Y. pestis, Brucella, Orthopox)</li>
<li>Routine work at containment level 3 for manipulation and growth of ACDP and SAPO 3 pathogens for use in research and trial diagnostics</li>
<li>Evaluation of commercial kits for use within RIPL in line with IVDR 2022</li>
<li>Collaborating with Viruses & Pathogenicity (V&P) and Comparative Genomics teams to identify unknown isolates and establish the cause of high consequence infections</li>
<li>Regularly performing bioinformatic reviews of in-house assays to confirm tests enable identification of all or typical circulating lineages/strains of pathogens</li>
<li>Participate in the 24-hour on-call molecular diagnostic service for viral haemorrhagic fevers</li>
<li>Training junior members of staff to use newly implemented/developed diagnostics</li>
<li>Use of a wide range of molecular platforms including QuantStudio 7, LightCycler 480, ABi Viia7 and Mic, as well as automated robotic systems such as the QIAGEN Qiagility, Tecan Freedom Evo and Dynex DS2</li>
<li>Working within regulated environments and conforming to ISO 9001, GLP and UKAS standards</li>
<li>Undergo vaccinations against a wide range of bacterial and viral pathogens</li></p></ul>


</div>
<button class="collapsible">Research Scientist – Microgenetics</button>
<div class="content">
<b><p align="justify">August 2018 - March 2019 <br></b></br>Research scientist position within the R&D team of Microgenetics Ltd. involved in the development and expansion of the SwiftDetect test for rapid single-cell microbial detection, with a focus on tuberculosis and pharmaceutical sterility testing. Duties included:
<ul>

<li>Research and development into new diagnostic areas including water, food and biodefense.</li>
<li>
Involved in automating SwiftDetect, using robotic pipettors and adaptation of existing labware for use in automated lab processes.
</li>
<li>Liaising with collaborative partners including Bristol University and Leicester University  
</li>
<li>Responsible for attendance at diagnostic and molecular microbiology conferences, networking and generating collaborative links with other universities. </p></li>
<ul></div>

<button class="collapsible">Research Asisstant – Cardiff University, School of Pharmacy</button>
<div class="content">
<b><p align="justify">September 2013 - September 2015 <br></b></br>
Professional Training Year (September 2013 - September 2014) in which practical and working knowledge of techniques including cloning, PCR, proteomics and ELISAs. Research project focussed on bacteriophages of <i>Bacillus anthracis</i>. Involved with numerous internal and external collaborators including NATO, Dstl and Battelle. Returned for short employment (June 2015 - September 2015) to complete phage decontamination work.</p>

<ul></div>


<h2>
Publications</h2>
<ul>
<h3><left-align>2021</left-align></h3>

 <li>COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study.<i> Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, Wellington E, Stowe J, Gillson N, Atti A, Islam J, Karagiannis I, Munro K, Khawam J, Chand MA, Brown CS, Ramsay M, Lopez-Bernal J, Hopkins S and <b><u>SIREN Study Group.</b></u></i><b> The Lancet, 2021</b>
(<a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00790-X/fulltext#%20" target="_blank">10.1016/S0140-6736(21)00790-X</a>).</li><ul>

</ul>

<li>BNT162b2 Vaccination in People Over 80 Years of Age Induces Strong Humoral Immune Responses with Cross Neutralisation of P.1 Brazilian Variant.

<i> Parry H, Tut G, Faustini S, Stephens C, Saunders P, Bentley C, Hilyard K, Brown K, Amirthalingam G, Charlton S, Leung S, Chiplin E, Coombes NS, Bewley K, Penn EJ, Rowe R, <b><u>Otter AD</u></b>,  Watts R, D’Arcangelo S, Hallis B, Makin A, Richter A, Zuo J, Moss P.</i>

<b>SSRN, 2021 </b>(<a href="https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3816840" target="_blank">10.2139/ssrn.3816840</a>). <b><i></b></li></i>
<ul>
<li>Press coverage: 

<a href="https://www.independent.co.uk/news/health/coronavirus-pfizer-vaccine-immune-elderly-b1825575.html" target="_blank">The Independent</a>, 

<a href="https://www.theguardian.com/world/2021/apr/01/pfizer-vaccine-has-91-efficacy-for-up-to-six-months-trial-shows" target="_blank">The Guardian</a>, 

<a href="https://medicalxpress.com/news/2021-04-dual-dose-pfizer-covid-vaccine.html" target="_blank">MedicalXpress</a>.
</li>
</ul>


<li>Impact of COVID-19 vaccination program on seroprevalence in blood donors in England, 2021.

<i>Whitaker H, Elgohari S, Rowe C, <b><u>Otter AD</u></b>, Brooks T, Linley E, Hayden I, Ribeiro S, Hewson J, Lakhani A, Clarke E, Tsang C, Campbell C, Ramsay ME, Brown K, Amirthalingam G.</i>

<b>SSRN, 2021 </b>(<a href="https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3803380" target="_blank">10.2139/ssrn.3803380</a>). <b><i></b></li></i>


<li>Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals.

<i>Manisty C*, <b><u>Otter AD*</u></b>, Treibel TA, McKnight A, Altmann DM, Brooks T, Noursadeghi M, Boyton RJ, Semper A, Moon JC.</i>

<b>The Lancet, 2021, 397 (10279), 1057-1058 </b>(<a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00501-8/fulltext" target="_blank">10.1016/S0140-6736(21)00501-8</a>). <b><i></b> * - Joint first author.</li></i><ul>
<li>Press coverage: <a href="https://www.nytimes.com/2021/02/26/world/pfizer-vaccine-protection.html target="_blank">New York Times</a>, <a href="https://edition.cnn.com/2021/02/26/health/pfizer-vaccine-covid-19-one-dose-uk-study-wellness/index.html" target="_blank">CNN</a>, <a href="https://www.mirror.co.uk/news/uk-news/one-dose-pfizer-vaccine-could-23575641" target="_blank">The Mirror</a>, <a href="https://www.telegraph.co.uk/news/2021/02/26/single-pfizer-vaccine-dose-could-enough-people-have-had-covid/" target="_blank">The Telgraph</a>.</li>
</ul>


<li>Rapid Antigen detection for SARS-CoV-2 by lateral flow assay: a national systematic evaluation for mass-testing.

<i>
Peto T, <b><u>UK COVID Lateral Flow Oversight Team</b></u>.</i>

<b>medRxiv, 2021 </b>(<a href="https://www.medrxiv.org/content/10.1101/2021.01.13.21249563v2" target="_blank">10.1101/2021.01.13.21249563</a>). <b><i></b></li></i>



<h3><left-align>2020</left-align>
</h3>

<li>Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection.

<i>
Reynolds CJ, Swadling L, Gibbons JM, Pade C, Jensen MP, Diniz MO, Schmidt NM, Butler DK, Amin OE, Bailey SNL, Murray SM, Pieper FP, Taylor S, Jones J, Jones M, Lee WYJ, Rosenheim J, Chandran A, Joy G, Genova CD, Temperton N, Lambourne J, Cutino-Moguel T, Andiapen M, Fontana M, Smit A, Semper A, O’Brien B, Chain B, Brooks T, Manisty C, Treibel T,  Moon JC, <b><u>COVIDsortium investigators</b></u>, Noursadeghi M, COVIDsortium immune correlates network, Altmann DM, Maini MK, McKnight A, Boyton RJ.</i>

<b> Science Immunology, 2020, 5 (54)</b>
(<a href="https://immunology.sciencemag.org/content/5/54/eabf3698" target="_blank">10.1126/sciimmunol.abf3698</a>). <b><i></b></li></i><ul>
<li>Press coverage: 

<a href="https://www.msn.com/en-in/news/world/lasting-immunity-against-covid-19-found-after-mild-or-asymptomatic-infection-study/ar-BB1chRTs?li=AAgges1&srcref=rss" target="_blank">MSN News</a>, 

<a href="https://www.iflscience.com/health-and-medicine/mild-and-asymptomatic-covid19-cases-have-some-longterm-immunity-to-virus/" target="_blank">IFLScience</a>, 

<a href="https://medicalxpress.com/news/2020-12-evidence-immunity-mild-asymptomatic-covid-.html" target="_blank">MedicalXpress</a>.
</li>
</ul>

<li>Characterising heterogeneity and sero-reversion in antibody responses to mild SARS-CoV-2 infection: a cohort study using time series analysis and mechanistic modelling.

<i>
Manisty C, Treibel TA, Jensen M, Semper A, Joy G, Gupta RK, Cutino-Moguel T, Andiapen M, Jones J, Taylor S, <b><u>Otter A</b></u>, Pade C, Gibbons JM, Lee WYJ, Jones M, Williams D, Lambourne J, Fontana M, Altmann DM, Boyton RJ, Maini M, McKnight A, Brooks T, Chain B, Noursadeghi M, Moon JC, COVIDsortium Investigators</i>

<b> medRxiv, 2020 </b>
(<a href="https://www.medrxiv.org/content/10.1101/2020.11.04.20225920v2" target="_blank">10.1101/2020.11.04.20225920</a>). <b><i>Now published in <a href="https://www.sciencedirect.com/science/article/pii/S2352396421000529" target="_blank">EBioMedicine.</a></b></li></i>



<li>Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: June to November 2020. <i>Hall V, Foulkes S, Charlett A, Atti A, Monk EJM, Simmons R, Wellington E, Cole MJ, Saei A, Oguti B, Munro K, Wallace S, Kirwan PD, Shrotri M, Vusirikala A, Rokadiya S, Kall M, Zambon M, Ramsay M, Brooks T, <b><u>SIREN Study Group</b></u>, Brown CS, Chand MA, Hopkins S.</i><b> medRxiv, 2020</b>
(<a href="https://www.medrxiv.org/content/10.1101/2021.01.13.21249642v1" target="_blank">10.1101/2021.01.13.21249642</a>). <b><i>Now published in <a href="https://www.sciencedirect.com/science/article/pii/S0140673621006759" target="_blank">The Lancet.</a></b></li><ul></i>
<li>Press coverage: 

<a href="https://www.theguardian.com/australia-news/2021/jan/30/immunological-unicorn-the-australian-lab-growing-coronavirus-and-its-startling-discovery" target="_blank">The Guardian</a>, 

<a href="https://uk.news.yahoo.com/covid-19-vaccines-probably-less-123542575.html" target="_blank">Yahoo!</a>, 

<a href="https://www.msn.com/en-gb/news/world/what-we-know-about-covid-reinfection-immunity-and-vaccines/ar-BB1dDgOU" target="_blank">MSN News</a>.
</li>
</ul>

<li>Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison.

<i>
<b><u>The National SARS-CoV-2 Serology Assay Evaluation Group</b></u>.</i>

<b>The Lancet Infectious Diseases, 2020, 20 (12), 1390-1400</b>
(<a href="https://www.sciencedirect.com/science/article/pii/S1473309920306344" target="_blank">10.1016/S1473-3099(20)30634-4</a>). <b><i></a></b></li></i>

  <li>A novel inducible prophage from <i>Burkholderia vietnamiensis</i> G4 is widely distributed across the species and has lytic activity against pathogenic Burkholderia.<i> Weiser R, Yap ZL, <b><u>Otter A</b></u>, Jones BV, Salvage J, Parkhill J, Mahenthiralingam E </i>. <b>Viruses, 2020, 12 (6), 601</b> (<a href="https://www.mdpi.com/1999-4915/12/6/601" target="_blank">10.3390/v12060601)</a>.</li>
</ul>

  <h2>
Other work
</h2>
<ul>
  <li>COVID-19: laboratory evaluations of serological assays. <a href="https://www.gov.uk/government/publications/covid-19-laboratory-evaluations-of-serological-assays" target="_blank">Public Health England</a>. </b>April 2020 - May 2021</b>.</li>
  <ul><li>Evaluation reports for multiple commericial serology platforms for the detection of anti-SARS-CoV-2 antibodies. </li></ul>
  <li>National flu and COVID-19 surveillance reports. <a href="https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports" target="_blank">Public Health England</a>. </b>April 2020 - May 2021</b>.</li>
  <ul><li>Weekly reports containing sero-prevalence data generated within my lab.</li></ul>
  </ul>
  
<h2>
Presentations
</h2>
<ul>
<li><i>Otter AD</i>. Variants of concern and serology. <b><a href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-2-global-serologic-study-for-covid-19" target="_blank">World Health Organisation, Solidarity II</a>. </b>March 2021</b>.</li>
<li><i>Otter AD</i>. Meet the Bioscience Alumni. <b>Cardiff University School of Biosciences</b>. March 2021. </li>
<li><i>Otter AD</i>. From Anthrax to SARS-CoV-2, the inadvertent path to a career in public Health.<b> The University of Bradford</b>. March 2021.</li>
<li><i>Otter AD</i>. From Anthrax to SARS-CoV-2, the inadvertent path to a career in public Health.<b> The University of Kent</b>. February 2021.</li>
<li><i>Otter AD</i>. SARS-CoV-2 virology and diagnostics.<b> The University of Plymouth</b>. November 2020.</li>
<li><i>Otter AD</i>. Understanding the role of Rv1255c, a TetR regulator absent from all <i>Mycobacterium bovis</i> strains.<b> The Jenner Institute</b>. August 2018.</li>
  <li><i>Otter AD</i>. CATs: controlling the hunger of <i>M. tuberculosis</i>? <b>Royal Society of Medicine</b>. October 2016.</li>
</ul>

<h2>Education</h2>
<button class="collapsible">University of London (RVC) – PhD</button>
<div class="content">
<b><p align="justify">September 2015 - September 2018 <br></b></br>
 PhD project focussed on transcriptional regulators of <i>Mycobacterium tuberculosis</i> under supervision from Dr. Sharon Kendall. Work included: <ul>
  <li>Routine culture of <i>M. tuberculosis</i> and <i>M. bovis</i> at CL3, conforming to SAPO safety regulations </li>
<li>Generation of unmarked mutants using homologous recombination
</li> 
<li>Molecular biology techniques such as qPCR, EMSAs, cloning, recombinant protein expression/purification and GFP reporter assays</li>
<li>Microbiological assays including growth curves, REMAs and macrophage infection, both at CL2 (<i>M. marinum</i>) and CL3 (<i>M. tuberculosis</i>).
<li>Bioinformatic analysis of >5,000 <i>M. tuberculosis</i> strains to identify modern and ancient specific SNPs in regulatory elements</li>

  </ul></p>
</div>
<button class="collapsible">Cardiff University – BSc. (Hons) Microbiology</button>
<div class="content">
<b><p align="justify">September 2011 - June 2015 <br></b></br>  
  Bachelor of Science degree, with professional training year and research lab dissertation. Final mark: First class honours (72%)</p>
</div>

<script>
var coll = document.getElementsByClassName("collapsible");
var i;

for (i = 0; i < coll.length; i++) {
  coll[i].addEventListener("click", function() {
    this.classList.toggle("active");
    var content = this.nextElementSibling;
    if (content.style.maxHeight){
      content.style.maxHeight = null;
    } else {
      content.style.maxHeight = content.scrollHeight + "px";
    } 
  });
}
</script>

</body>
</html>
